Startups Plan the Health Data Gold Rush

Companies are building platforms based on blockchain technology to let individuals control and directly profit from their genomic and medical information.

Written byShawna Williams
| 8 min read

Register for free to listen to this article
Listen with Speechify
0:00
8:00
Share

ABOVE: © ISTOCK.COM, RICK_JO

Even if you’ve never heard of IQVIA, the company most likely knows some things about you—if only in anonymized form. As Harvard University fellow Adam Tanner documents in his 2017 book Our Bodies, Our Data, IQVIA (formerly IMS Health), along with other companies such as IBM and Lexis-Nexus, regularly pay health care providers, pharmacies, clinical labs, and insurers for patients’ de-identified health records, prescribing data, insurance claims, and other information. Then they collate and sell this information to pharmaceutical companies and others who rely on such data for research and marketing. And business is good: IQVIA reported revenue of $2.5 billion in the second quarter of this year.

Until now, the proceeds from the booming health data–brokering industry have seldom been seen by the people who contribute the information in the first place. But that could be about to change, thanks to a new class of ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Related Topics

Meet the Author

  • Shawna was an editor at The Scientist from 2017 through 2022. She holds a bachelor’s degree in biochemistry from Colorado College and a graduate certificate in science communication from the University of California, Santa Cruz. Previously, she worked as a freelance editor and writer, and in the communications offices of several academic research institutions. As news director, Shawna assigned and edited news, opinion, and in-depth feature articles for the website on all aspects of the life sciences. She is based in central Washington State, and is a member of the Northwest Science Writers Association and the National Association of Science Writers.

    View Full Profile

Published In

October 2018

Bright Lights, Big Problems

Scientists are exploring the ecological damage caused by artificially lit night skies

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies